Unknown PHASE2 INTERVENTIONAL 2-arm NCT02605811

Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer

Radiation Versus Temozolomide in Preventing Brain Metastases in Limited Stage Small Cell Lung Cancer

Sponsor: Guangzhou Medical University

Conditions Metastatic Carcinoma Small Cell Lung Cancer

Interventions prophylaxis cranial radiotherapy temozolomide

Updated 7 times since 2017 Last updated: Mar 27, 2019 Started: Sep 30, 2015 Primary completion: Dec 31, 2019 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02605811, this PHASE2 trial focuses on Metastatic Carcinoma and Small Cell Lung Cancer and remains ongoing. Sponsored by Guangzhou Medical University, it has been updated 7 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Mar 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Mar 2022 [monthly]

Recruiting PHASE2
Apr 2019 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Enrolling By Invitation → Recruiting

▶ Show 2 earlier versions

Jun 2018 — Apr 2019 [monthly]

Enrolling By Invitation PHASE2
Jan 2017 — Jun 2018 [monthly]

Enrolling By Invitation PHASE2

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangzhou Medical University

Data source: Guangzhou Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China